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Abstract
Background: Leptin is associated with cardiovascular disease (CVD); however, few studies have assessed its
relationship with metabolic syndrome, especially in an Asian population. Therefore, the aim of the present study
was to assess leptin levels and evaluate its association with CVD and metabolic syndrome.
Methods: In 2009, 957 subjects, who underwent a routine physical examination and choose leptin examination,
were selected to participate. Participants (269 females and 688 males) were stratified according to leptin level
quartiles. Metabolic syndrome was defined by NCEP ATP III using waist circumference cutoffs modified for Asian
populations, and CVD risk was determined using the Framingham Heart Study profile.
Results: Leptin levels were correlated with CVD risk in men and women. With the exception of fasting plasma
glucose, increased leptin levels were observed as factors associated with metabolic syndrome increased in both
males and females. After adjusting for age, an association between leptin levels and metabolic syndrome was
observed. After adjusting for age alone or with tobacco use, subjects in the highest leptin quartile had a higher
risk of having metabolic syndrome than those in the lowest quartile (OR = 6.14 and 2.94 for men and women,
respectively). After further adjustment for BMI, metabolic syndrome risk remained significantly increased with
increasing leptin quartiles in men. Finally, increased leptin levels were a predictor of metabolic syndrome in men
and women.
Conclusions: Serum leptin levels are correlated with CVD risk and metabolic syndrome. Analysis of leptin as part of
routine physical examinations may prove beneficial for early diagnosis of metabolic syndrome.
Keywords: Taiwan obesity, metabolic syndrome
Introduction
Metabolic syndrome is a major risk factor for type 2
diabetes mellitus and cardiovascular disease (CVD).
Specifically, a three-fold increase in the prevalence of
metabolic syndrome is associated with a two-fold
increased risk of cardiovascular disease fatality, 150%
increase in total mortality, and a five-fold increased risk
of diabetes mellitus [1]. Because metabolic syndrome is
associated with increased risk for CVD and diabetes
mellitus [2-5], early diagnosis of metabolic syndrome
and resultant intervention strategies may help reduce
the incidence of these associated diseases.
Leptin is important for body weight regulation. In mice,
mutations of the OB gene on chromosome 7, which
encodes the leptin protein, results in obesity and type 2
diabetes [6]. The amount of leptin secreted by white adi-
pose tissue is proportional to the volume of body adipose
tissue; therefore, adiposity greatly influences leptin levels.
In addition, other factors, including rapid or excessive
food intake, sleep, body temperature, gender, circadian
rhythm, and other hormones such as insulin, growth
hormone, glucocorticoids, testosterone, and thyroid
hormone, impact leptin secretion and expression.
Elevated serum leptin concentration is a feature of
obesity and abdominal adiposity, a risk factor for
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is not considered among the diagnostic criteria for
metabolic syndrome, it is increased in subjects with
metabolic syndrome [7-9].
Because leptin has a certain degree of influence on
appetite, energy consumption, adipose synthesis, and
insulin function, elevated serum leptin levels are com-
mon in human obesity. The higher the body mass index
(BMI) or the waist circumference, the higher the serum
leptin level [10]. The elevated concentration of circulat-
ing leptin has been consistently associated with other
cardiometabolic risk factors, such as hypertension, insu-
lin resistance, and type 2 diabetes [11-18]; however, few
studies have analyzed its association with metabolic syn-
drome [7-9]. Of the few conducted, few have analyzed
Asian populations. Thus, the objective of the present
study was to assess the association of leptin with meta-
bolic syndrome and CVD risk in Taiwanese adults as
well as the predictive value of leptin levels for identify-
ing patients with metabolic syndrome. Leptin levels
were measured in adult participants undergoing a rou-
tine physical examination, and their relationship with
metabolic syndrome as well as CVD risk was assessed.
Materials and methods
Study participants
In 2009, 988 subjects > 18 years of age, who underwent a
routine physical examination and choose leptin examina-
tion in Chang-Gung Memorial Hospital-Linkou (North
Taiwan) and Chiayi (South Taiwan), were selected to
participate in this retrospective study. Questionnaires were
completed at the Health Examination Centers in the
Linkou and Chiayi branches of Cheng-Gung Memorial
Hospital; the physical examination and venous blood sam-
pling was obtained at the same time. Analysis excluded
subjects that did not fast for more than 10 h prior to
blood sampling, were pregnant, those with chronic
diseases that significantly impact the metabolic functions,
such as thyroid diseases, chronic hepatitis, liver cirrhosis,
hypothalamus disease, etc., and those with a history of
illness or medication use in the questionnaires. There
were 31 subjects excluded from this study based on the
exclusion criteria. Therefore, a total of 957 participants
(688 males, average age of 35.2 y [SD = 7.2 y] and
269 females, average age of 38.5 y [SD = 11.8 y])
were included for this study. The study protocol was
approved by the Institutional Review Board of Chang-
Gung Memorial Hospital.
Clinical and biochemical measurements
Participants were interviewed using questionnaires by
trained nurses. Information regarding demographic (e.g.,
age, gender, etc.) and life style (e.g., experience of
smoking, drinking, etc.) characteristics, history of illness
and medication use, and physiologic status (pregnancy,
fasting time, etc.) was collected.
Blood pressure was measured after the participants
were at rest for 10 min using an automatic sphygmoman-
ometer to the right arm while the individuals were in a
sitting position. An additional 5-minute break was given
between measurements for participants with systolic
blood pressure > 140 mmHg or the diastolic blood pres-
sure > 90 mmHg. The lowest value was used after 2 to 3
measurements. The participant’s weight and height was
measured without shoes and after fasting. BMI was calcu-
lated as weight (kg) divided by the square of height (m
2).
Waist circumference was measured midway between the
iliac crest and the lower margin of the 12
th rib.
After a 12-h fast, venous blood samples were obtained
from 5:30 to 11:00 a.m. and stored at 4°C. Total choles-
terol, high-density lipoprotein cholesterol (HDL-C),
triglyceride (TG), fasting blood glucose (FBG), low-density
lipoprotein cholesterol (LDL-C), uric acid, homocysteine,
and leptin levels were determined for each participant.
Definition of metabolic syndrome
A diagnosis of metabolic syndrome was defined as a
subject presenting at least 3 of the 5 factors for meta-
bolic syndrome described by the Third Adult Treatment
Panel (ATP III) of the National Cholesterol Education
Program (NCEP) [19]. The diagnostic criteria were
defined as follows: 1) high blood pressure (a systolic
blood pressure ≥ 130 mmHg and/or diastolic pressure ≥
85 mmHg, under treatment, or already diagnosed with
hypertension); 2) high serum triglyceride (≥ 150 mg/dL
or under treatment); 3) decreased HDL-C (< 40 mg/dL
for males and < 50 mg/dL for females or under treat-
ment); 4) hyperglycemia (FBG ≥ 100 mg/dL, under
treatment, or previously diagnosed with diabetes melli-
tus); and abdominal obesity. Waist circumference cutoffs
were modified for Asian populations [20]. A waist cir-
cumference ≥ 90 cm for men and ≥ 80 cm for women
plus the other two risk factors or the waist circumstance
within the threshold plus the other three or more risk
factors resulted in a diagnosis of metabolic syndrome.
Cardiovascular disease risk percentage definition
CVD risk was analyzed based upon the profile described
by D’Agostino et al. [21]. This profile predicts the risk of
developing all CVD events, including coronary death,
myocardial infarction, coronary insufficiency, angina,
ischemic stroke, hemorrhagic stroke, transient ischemic
attack, peripheral artery disease, heart failure, using sex-
specific multivariable risk functions that incorporated
age, total cholesterol, HDL-C, systolic blood pressure,
treatment for hypertension, smoking, and diabetes status.
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Serum leptin levels were categorized into quartiles
(Q1-4) according to the leptin levels (Q1, < 2.4 ng/mL;
Q2, 2.4 to < 4.2 ng/mL; Q3, 4.2 to < 6.65 ng/mL; and
Q4 ≥ 6.65 ng/mL for males and Q1, < 6.8 ng/mL; Q2,
6.8 to <9.0 ng/mL; Q3, 9.0 to < 13.1 ng/mL; and Q4, ≥
13.1 ng/mL for females). The data were presented as
mean ± standard deviation (SD) for continuous variables
and n (%) for categorical variables. Clinical characteris-
tics were compared using one-way ANOVA for continu-
ous variables and Chi-sqaure or Fisher’se x a c tt e s tf o r
categorical variables. Spearman’s rank correlation was
performed for each gender to assess the relationship
between leptin levels and cardiometabolic risk factors.
General linear model analysis was applied to identify the
association of leptin levels with cardiometabolic risk fac-
tors after adjusting for age and tobacco usage. In addi-
tion, a binary logistic regression model was used to
evaluate the association of leptin levels with metabolic
syndrome after adjusting for age, tobacco usage, and
BMI. A received operating curve (ROC) for leptin level
as a predictor of metabolic syndrome was also carried
out. Statistical analyses were performed using the SPSS
15.0 software package (SPSS, Inc., Chicago, IL). A
P-value < 0.05 was considered statistically significant.
Results
The characteristics of male and female participants stra-
tified by leptin quartiles are shown in Table 1. The
mean leptin level for the study participants was 1.42 ng/
mL. The prevalence of metabolic syndrome was 61% in
the study population. In men and women, participants
in Q4 were more likely to have factors associated with
metabolic syndrome, including increased waist circum-
ference, triglyceride, and blood pressure and decreased
HDL-C. No significant differences in FBG were
observed. In addition, no differences in tobacco usage
and homocysteine level were observed (Table 1).
Furthermore, those with metabolic syndrome were more
likely to be in the upper leptin quartiles. Finally, percen-
tage of CVD risk significantly increased with increasing
leptin levels in both men and women.
The relationship between increased leptin levels and
CVD risk percentage was also analyzed using the
Kruskal Wallis test. Increased CVD risk percentage was
observed in Q4 as compared to patients with leptin
levels within Q1 and Q2 in both men and women
(Figure 1, p < 0.05).
As shown in Table 2, Spearman’s rank correlation (rs)
analysis of leptin level with cardiometabolic risk factors
for men and women was undertaken. In both men and
women, leptin levels were positively correlated with
BMI, waist circumference, blood pressure, total choles-
terol, triglyceride, FPG, uric acid, LDL cholesterol, and
percentage of CVD risk, but negatively correlated with
HDL cholesterol. In addition, age was positively corre-
lated with leptin levels in women (Table 2).
Univariate linear regression analysis after adjusting for
age or multiple variables, including age, tobacco usage,
and BMI, to determine the association of leptin levels
with cardiometabolic risk factors was assessed (Table 3).
After adjusting for age, leptin levels were significantly
positively associated with BMI, waist circumference,
blood pressure, total cholesterol, triglyceride, uric acid,
LDL cholesterol, percentage CVD risk, and metabolic
syndrome, but were negatively associated with HDL
cholesterol in both men and women. After adjusting for
age, BMI, and tobacco usage, leptin levels were posi-
tively associated with metabolic syndrome in females
(Table 3).
The correlation between metabolic syndrome and
serum leptin quartiles was calculated independent of
age, tobacco usage, and BMI in three models using bin-
ary logistic regression analysis (Table 4). Specifically,
model 1 adjusted for age whereas models 2 and 3
adjusted for age and tobacco usage and age, tobacco
usage, and BMI, respectively. In men, compared to the
lowest leptin quartile, the odds ratio (OR) and 95% con-
fidence intervals (95% CI) for metabolic syndrome after
adjusting for age were 3.28 (2.06 - 5.20) in Q2, 5.12
( 3 . 1 3-8 . 3 7 )i nQ 3a n d6 . 1 4( 3 . 7 0-1 0 . 1 9 )i nQ 4( p <
0.001). A similar increase in odds ratio was observed in
women (Q4 vs. Q1, 2.94 (1.36 - 6.37), p =0 . 0 3 7 ) .
Further adjusting for tobacco usage and BMI revealed
increased odds ratio of metabolic syndrome in men only
(Q4 vs. Q1, 6.15 (3.71 - 10.21) and 2.66 (1.39 - 5.11),
p ≤ 0.001 for models 2 and 3, respectively); a signifi-
cantly increased odds ratio was only seen in model 2 for
women (Table 4).
The relationship between leptin levels and metabolic
syndrome was further explored using ROC analysis to
determine the predictive value of leptin levels for meta-
bolic syndrome in men and women (Figure 2). As leptin
levels increased, the incidence of metabolic syndrome
also significantly increased in both men (0.676 [SE =
0.022]) and women (0.627 [SE = 0.035]); Figure 2a-1
and 2b-1, respectively). The predictive value of leptin
levels for metabolic syndrome was not diminished upon
adjusting for age (Figure 2a-2 and 2b-2), age and
tobacco usage (Figure 2a-3 and 2b-3), and age, tobacco
usage, and BMI (Figure 2a-4 and 2b-4) in either sex.
Discussion
In the present study, serum leptin levels were associated
with metabolic syndrome as well as cardiovascular risk
in an adult Taiwanese population. Specifically, partici-
pants with higher leptin levels had increased metabolic
risk factors as compared to those with lower leptin
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syndrome was observed in both male and female partici-
pants. Moreover, serum leptin levels were predicative of
metabolic syndrome in both sexes.
Although few, population studies describing the rela-
tionship between leptin levels and metabolic syndrome
have been reported [7-9]. For example, in obese and
nonobese Caucasian children, leptin levels were asso-
ciated with metabolic syndrome [8]. In the Cyprus
Metabolism Prospective Cohort Study, leptin as well as
its soluble receptor was not only associated with base-
line adiposity and metabolic risk factors, but also
predicted adiposity, metabolic syndrome, and glucose
levels in eighteen-year-old men [22]. Furthermore, in
the Framingham Third Generation Cohort, leptin con-
centrations were associated with increased odds of
metabolic syndrome [23]. Importantly, reductions in
leptin levels in obese children (mean age: 14.1 y)
predicted short- and long-term reductions in body fat
and improved lipid levels and insulin sensitivity, suggest-
ing that children retain leptin sensitivity [24]. Reducing
daily caloric intake by 500 kilocalories resulted in a
5-10% decrease in body weight, decreased BMI, and a
25% fall in leptin plasma concentrations [25].
Table 1 General characteristics of the study population according to sex-specific leptin levels
Leptin levels
Characteristics Q1 Q2 Q3 Q4 P-value
c
Men (n = 149) (n = 186) (n = 181) (n = 171)
Age
a, y 34.9 ± 7.7 34.5 ± 6.8 36.5 ± 8.6 34.7 ± 5.3 0.041*
Body mass index
a, kg/m
2 21.5 ± 2.3 23.6 ± 2 25.7 ± 2.5 27.8 ± 3.2 < 0.001*
Waist circumference
a, cm 76.1 ± 5.9 82.2 ± 5 87.9 ± 6.9 92.7 ± 7.7 <0.001*
Tobacco usage
b, n (%) 65 (43.6) 76 (40.9) 77 (42.5) 75 (43.6) 0.947
Systolic blood pressure
a, mm Hg 119.6 ± 9.7 122 ± 11.2 125.9 ± 11.9 127.7 ± 13.7 < 0.001*
Diastolic blood pressure
a, mm Hg 74.7 ± 7.1 76.3 ± 8.2 78.4 ± 7.5 81.3 ± 9.9 < 0.001*
Total cholesterol
a, mg/dL 179.5 ± 29.5 189.4 ± 28.6 192.2 ± 31 198.6 ± 36.8 < 0.001*
Triglyceride
a, mg/dL 91.2 ± 44.4 128.2 ± 114.6 144.3 ± 83.5 153.8 ± 87 < 0.001*
Fasting plasma glucose
a, mg/dL 89.1 ± 19.2 90.5 ± 19.5 92.1 ± 14.8 93.2 ± 13.4 0.135
Uric acid
a, mg/dL 6.2 ± 1 6.7 ± 1.3 6.9 ± 1.2 7.2 ± 1.3 < 0.001*
HDL cholesterol
a, mg/dL 56.6 ± 13.2 51.2 ± 11.2 47.5 ± 9.2 46.9 ± 9.2 < 0.001*
LDL cholesterol
a, mg/dL 115.5 ± 27.5 126.1 ± 26.2 131 ± 29.3 137.6 ± 33.3 < 0.001*
Homocysteine
a, umol/L 10.5 ± 3 10.2 ± 3.3 10.1 ± 3.3 10.8 ± 5.7 0.338
Leptin
a, ng/mL 1.4 ± 0.6 3.2 ± 0.5 5.2 ± 0.7 10.3 ± 4.7 < 0.001*
Metabolic syndrome
b, n (%) 60 (40.3) 125 (67.2) 141 (77.9) 137 (79.7) < 0.001*
Percentage of CVD risk
a 2.47 ± 4.14 3.49 ± 4.36 5.03 ± 4.69 4.91 ± 4.02 < 0.001*
Women (n = 65) (n = 67) (n = 68) (n = 69)
Age
a, y 36.5 ± 11.3 37.7 ± 12 38.5 ± 10.9 41.3 ± 12.7 0.111
Body mass index
a, kg/m
2 19.8 ± 2 20.9 ± 1.9 22.1 ± 2.4 24.8 ± 3.6 <0.001*
Waist circumference
a, cm 68.6 ± 7 69.6 ± 5.6 73 ± 7.3 79.4 ± 10.3 < 0.001*
Tobacco usage
b, n (%) 4 (6.2) 3 (4.5) 2 (2.9) 2 (2.9) 0.717
Systolic blood pressure
a, mm Hg 110.7 ± 13.4 110.2 ± 11.1 112.5 ± 13.8 118.2 ± 15.2 0.002*
Diastolic blood pressure
a, mm Hg 69.9 ± 8.4 68.6 ± 6.9 70.7 ± 10.2 73.7 ± 7.2 0.004*
Total cholesterol
a, mg/dL 180.4 ± 30.9 181 ± 33.3 187 ± 28.9 195.9 ± 33.3 0.016*
Triglyceride
a, mg/dL 84.1 ± 60.4 85.1 ± 98.5 90.5 ± 42.8 123.9 ± 82.8 0.005*
Fasting plasma glucose
a, mg/dL 87.7 ± 24.3 88.9 ± 12.8 87.5 ± 7.4 92.2 ± 17.7 0.325
Uric acid
a, mg/dL 4.7 ± 0.8 4.6 ± 0.9 4.9 ± 1.1 5.3 ± 1.1 <0.001*
HDL cholesterol
a, mg/dL 64.2 ± 14.2 63.6 ± 12.2 61.2 ± 13.9 57.6 ± 11.6 0.016*
LDL cholesterol
a, mg/dL 107.8 ± 28.6 109.4 ± 28.9 117.5 ± 26.4 126.5 ± 31.7 0.001*
Homocysteine
a, umol/L 7.8 ± 1.9 7.6 ± 1.7 7.6 ± 1.7 7.8 ± 1.4 0.727
Leptin
a, ng/mL 4.8 ± 1.3 7.5 ± 0.6 10.9 ± 1.3 17.6 ± 3.9 < 0.001*
Metabolic syndrome
b, n (%) 21 (32.3) 26 (38.8) 31 (45.6) 43 (62.3) 0.003*
Percentage of CVD risk
a -0.38 ± 4.14 0.19 ± 5.01 0.75 ± 5.41 2.72 ± 6.39 0.005*
Serum leptin levels were categorized into quartiles (Q1-4) according to the leptin levels (Q1, < 2.4 ng/mL; Q2, 2.4 to < 4.2 ng/mL; Q3, 4.2 to < 6.65 ng/mL;a n d
Q4 ≥ 6.65 ng/mL for males and Q1, < 6.8 ng/mL; Q2, 6.8 to <9.0 ng/mL; Q3, 9.0 to < 13.1 ng/mL; and Q4, ≥ 13.1 ng/mL for females).
a,b Clinical characteristics were presented as mean ± SD for
acontinuous variables and n (%) for
bcategorical variables.
c P-values were derived through one-way ANOVA for continuous variables and Chi-square or Fisher’s exact test for categorical variables.
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the relationship between leptin levels and metabolic syn-
drome in an Asian population. In nondiabetic Taiwanese
adolescents, plasma leptin levels were positively corre-
lated to BMI, waist circumference, waist-to-hip ratio,
body fat mass, body fat mass percentage, and triglycer-
ides [7]. Furthermore, serum leptin was associated with
metabolic syndrome in obese and nonobese [26] as well
as diabetic [27] Korean populations. In addition, in
a 3-year follow-up study of Japanese children ages
9-10 years, leptin levels increased in those subjects
whose BMI increased during the follow-up period [28].
In the present study, increased odds of metabolic
syndrome with increasing leptin levels were observed in
both sexes upon adjusting for age and tobacco usage.
However, after further adjustment for BMI, increased
odds of metabolic syndrome with increased leptin levels
were only observed in men. Yun et al. [26] reported that
leptin levels were more strongly correlated to risk of
metabolic syndrome in men compared to women after
controlling for confounding variables. It remains possi-
ble that gender differences in body fat distribution or
effects of sex steroids may account for this result;
another possibility is many Taiwanese women keep their
weight on a diet, not performing exercise. That might
increase the body fat and the leptin level, but not influ-
ents the body weight or BMI. However, further studies
are necessary to determine the role in adipose distribu-
tion (visceral versus subcutaneous) or reproductive hor-
mones and metabolic syndrome.
Leptin levels were also predictive of metabolic syn-
drome in both sexes, which is similar to other studies.
For example, in adult males participating in the Olivetti
Prospective Heart Study, leptin levels were predictor of
developing metabolic syndrome at 8-year follow-up [29].
In addition, Franks et al. [30] reported that leptin levels
predict worsening of metabolic syndrome over time.
Leptin has a certain degree of influence on appetite,
energy consumption, adipose synthesis, and insulin
function. Acting as a hormone, leptin has a broad spec-
trum of biological function; the main effects are the reg-
ulation of adipose tissue and body weight [31-34]. First,
the inhibition of appetite and the consumption of body
energy are achieved through decreased neuropeptide Y
(NPY) secretion and hormone secretion of melanocytes,
resulting from the combination of leptin and its receptor
within the hypothalamus. Second, the increased con-
sumption of energy is achieved by releasing the heat,
transformed from the massive storage of energy. The
process is due to the increased activities of sympathetic
nerves induced by leptin and the activation of the epi-
nephrine receptor on the membranes of the adipose
cells. Third, the synthesis of the adipose tissue is directly
influenced by leptin, and the resorption can be acceler-
ated. Other researchers suspect that leptin can promote
the maturation of adipose cells [35]. Finally, leptin may
influence other hormones; insulin can accelerate the
secretion of leptin and, inversely, leptin has negative
feedback on the synthesis and secretion of insulin
[14,15,36-38].
Because leptin influences appetite, energy consump-
tion, adipose synthesis, and insulin function, investiga-
tors have explored the use of recombinant leptin as a
treatment for obesity. For example, in two severely
Figure 1 The distribution of CVD risk percentage by sex-
specific leptin levels. Data represent mean with standard error of
mean for each leptin quartile.
a significantly different (P < 0.0167) in
CVD risk % as compared with Q1.
b significantly different (P <
0.0167) in CVD risk % as compared with Q2.
Table 2
aSpearmen’s correlation of leptin levels with
cardiometabolic risk factors in men and women
Men Women
Cardiometabolic risk factors rs P-value rs P-value
Age, y 0.060 0.119 0.161 0.008*
Body mass index, kg/m
2 0.718 <0.001* 0.629 <0.001*
Waist circumference, cm 0.743 <0.001* 0.502 <0.001*
Tobacco usage (Yes vs. No) 0.012 0.744 -0.062 0.309
Alcohol usage (Yes vs. No) -0.002 0.948 -0.05 0.409
Systolic blood pressure, mm Hg 0.275 <0.001* 0.199 0.001*
Diastolic blood pressure, mm Hg 0.28 <0.001* 0.195 0.001*
Total cholesterol, mg/dL 0.203 <0.001* 0.185 0.002*
Triglyceride, mg/dL 0.364 <0.001* 0.298 <0.001*
Fasting plasma glucose, mg/dL 0.246 <0.001* 0.243 <0.001*
Uric acid, mg/dL 0.329 <0.001* 0.239 <0.001*
HDL cholesterol, mg/dL -0.337 <0.001* -0.227 <0.001*
LDL cholesterol, mg/dL 0.264 <0.001* 0.256 <0.001*
Homocysteine, umol/L -0.027 0.474 0.059 0.345
CVD risk, % 0.257 <0.001* 0.246 <0.001*
a The coefficient of Spearmen correlation were shown as rs with a P-value.
* P < 0.05.
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region was observed [39]. Improvements in fasting
serum glucose, insulin levels and glycosylated hemoglo-
bin were observed upon recombinant methionyl human
leptin therapy [39]. In addition, leptin therapy corrected
the excess appetite and promoted weight loss and pub-
erty initiation in one of the children [40]. However, the
single-leptin gene mutation only explains rare cases of
human obesity; only 5% of obese patients lack leptin.
Most patients are genetically stable and without the
single-gene mutation [41]. Despite the lack of leptin
mutations, leptin mRNA expression level in the adipose
tissue and the serum leptin levels have been positively
associated with the degree of obesity [42], suggesting
that leptin resistance might be one of the causes for
human obesity. However, use of recombinant leptin for
obesity has been relatively ineffective.
Obese individuals often have hyperleptinemia, suggest-
ing the presence of leptin resistance which is character-
ized by the persistence of overweight despite high leptin
Table 3
aUnivariate analysis of leptin levels with cardiometabolic risk factors after adjusting for age and tobacco
usage in men and women
Men Women
Age-adjusted Multivariable-adjusted
b Age-adjusted Multivariable-adjusted
b
Cardiometabolic risk factors B (SE) P-value B (SE) P-value B (SE) P-value B (SE) P-value
Body mass index, kg/m
2 0.810 (0.033) < 0.001* - 1.230 (0.079) < 0.001* -
Tobacco usage (Yes vs. No) 0.342 (0.313) 0.275 - -1.345 (1.601) 0.402 -
Alcohol usage (Yes vs. No) 0.174 (0.309) 0.573 0.006 (0.238) 0.978 0.152 (0.805) 0.851 -0.109 (0.608) 0.858
Waist circumference, cm 0.312 (0.013) <0.001* 0.147 (0.028) <0.001* 0.394 (0.032) <0.001* 0.074 (0.050) 0.135
Systolic blood pressure, mm Hg 0.095 (0.012) <0.001* 0.016 (0.010) 0.103 0.099 (0.026) <0.001* -0.038 (0.021) 0.074
Diastolic blood pressure, mm Hg 0.138 (0.017) <0.001* 0.026 (0.014) 0.074 0.130 (0.038) 0.001* 0.002 (0.029) 0.934
Total cholesterol, mg/dL 0.024 (0.005) <0.001* 0.008 (0.004) 0.030 0.021 (0.010) 0.043* 0.003 (0.008) 0.678
Triglyceride, mg/dL 0.008 (0.002) <0.001* 0.002 (0.001) 0.173 0.012 (0.004) 0.006* -0.003 (0.003) 0.351
Fasting plasma glucose, mg/dL 0.024 (0.010) 0.016* 0.007 (0.007) 0.323 0.024 (0.020) 0.242 -0.024 (0.015) 0.115
Uric acid, mg/dL 0.908 (0.116) <0.001* 0.199 (0.094) 0.034 1.378 (0.301) <0.001* 0.282 (0.245) 0.250
HDL cholesterol, mg/dL -0.079 (0.013) <0.001* 0.008 (0.011) 0.453 -0.081 (0.024) 0.001* -0.011 (0.018) 0.542
LDL cholesterol, mg/dL 0.030 (0.005) <0.001* 0.006 (0.004) 0.115 0.037 (0.011) 0.001* 0.011 (0.008) 0.167
Homocysteine, umol/L 0.060 (0.039) 0.121 0.039 (0.029) 0.175 0.034 (0.192) 0.860 -0.060 (0.140) 0.670
CVD risk, % 0.406 (0.049) <0.001* 0.096 (0.054) 0.076 0.556 (0.123) <0.001* -0.056 (0.105) 0.598
Metabolic syndromes (Yes vs. No) 2.089 (0.325) <0.001* 0.339 (0.256) 0.186 2.146 (0.685) 0.002* 0.338 (0.520) 0.032*
a The results of univariate analysis were shown as estimated beta (B), standard error of beta (SE), and P-value.
badjusted for age, BMI, and tobacco usage.
* P < 0.05, P-values were derived as for the significance of B from the general linear model analysis.
Table 4
aOdds ratio of metabolic syndromes with leptin levels by sex-specific quartiles
Leptin levels Model 1
c Model 2
d Model 3
e
Men
Q1 (n = 149) 1.00 1.00 1.00
Q2 (n = 186) 3.28 (2.06 - 5.20) 3.27 (2.06 - 5.19) 2.46 (1.52 - 4.01)
Q3 (n = 181) 5.12 (3.13 - 8.37) 5.11 (3.13 - 8.37) 2.94 (1.67 - 5.17)
Q4 (n = 171) 6.14 (3.70 - 10.19) 6.15 (3.71 - 10.21) 2.66 (1.39 - 5.11)
P-value for trend
b < 0.001* < 0.001* 0.001*
Women
Q1 (n = 65) 1.00 1.00 1.00
Q2 (n = 67) 1.27 (0.58 - 2.77) 1.26 (0.57 - 2.75) 1.11 (0.50 - 2.45)
Q3 (n = 68) 1.63 (0.76 - 3.50) 1.61 (0.75 - 3.46) 1.21 (0.54 - 2.71)
Q4 (n = 69) 2.94 (1.36 - 6.37) 2.90 (1.34 - 6.30) 1.55 (0.61 - 3.93)
P-value for trend
b 0.037 0.040 0.816
a The results were represented as estimated Odds ratio (OR) with a 95% confidence interval (95%CI).
b P-values for trend were derived from binary logistic regression model analysis.
c Model 1: adjusted for age.
d Model 2: adjusted for age and tobacco usage.
e Model 3: adjusted for age, tobacco usage, and BMI.* P < 0.05.
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Page 6 of 8concentrations. In leptin resistance, the higher leptin
concentrations muted the responses to decrease weight
[43]. It remains possible that the individuals with upper
quartile leptin levels had leptin resistance; however,
further studies are necessary to determine if these indi-
viduals were leptin resistant and if so, the mechanism
by which the leptin resistance manifests (e.g., the pre-
sence of leptin neutralizing antibodies or antagonists
[44], decreased leptin transport across the blood-brain
barrier [45], defective leptin signaling [46], etc.).
This study has some limitations that warrant discus-
sion. Firstly, the retrospective nature of the study pre-
vents determining the direction of causality for the
relationship between leptin and metabolic syndrome.
Secondly, leptin level is selective item of routine physical
examination, usually was chosen by subjects who are
aware of overweight or hyperlipidemia. So the preva-
lence of metabolic syndrome was a litter higher than
other studies. Furthermore, because the study popula-
tion consisted of only Taiwanese adults, the findings
may not carry over to other racial or ethnic groups.
In conclusion, serum leptin levels are correlated with
CVD risk and metabolic syndrome in Taiwanese adults.
Serum leptin levels could also predict metabolic syn-
drome; therefore, analysis of leptin as part of routine
physical examinations may prove beneficial in the early
diagnosis of metabolic syndrome.
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Figure 2 Receiver Operating Curve (ROC) analyses for leptin levels as a predictor of metabolic syndrome. ROC analysis was undertaken in
(a) men, and (b) women. a-1 and b-1, Leptin vs. Metabolic syndrome without adjustment. a-2 and b-2, age-adjusted. a-3 and b-3, age and tobacco
usage-adjusted. a-4 and b-4, age, tobacco usage, and BMI-adjusted. The area under the ROC curves were 0.676 (SE = 0.022), 0.907 (SE = 0.012), 0.906
(SE = 0.012), and 0.900 (SE = 0.013) in men and 0.627 (SE = 0.035), 0.729 (SE = 0.035), 0.735 (SE = 0.035), and 0.714 (SE = 0.035) in women.
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